Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Celgene Corporation (CELG - Analyst Report) recently announced positive results from the PALACE 4 study on apremilast. The study is evaluating apremilast (20 mg and 30 mg), a novel, oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), in patients suffering from psoriatic arthritis.

Results from the phase III study showed that apremilast achieved statistical significance for ACR 20 at week 16 in psoriatic arthritis patients across both dosage strengths. Results also revealed that the candidate showed benefit over placebo in other secondary objectives of the study. We note that the 52-week PALACE 4 study is currently underway.

Besides the PALACE 4 study, the PALACE program also consists of three more phase III studies (PALACE 1, PALACE 2 and PALACE 3) on apremilast in the psoriatic arthritis indication. We remind investors that Celgene presented encouraging data from the PALACE-2 and PALACE-3 studies in Sep 2012 and from the PALACE 1 study in Nov 2012. Top-line results from PALACE 3 study and 52-week results from PALACE 1 study are expected in June this year.

Earlier this year, Celgene submitted regulatory submissions for the approval of apremilast (psoriatic arthritis) in the US and Canada, based on the positive results from PALACE 1, 2 and 3 studies.

We note that apart from psoriatic arthritis, apremilast is also being developed for the treatment of psoriasis, ankylosing spondylitis, and Behçet’s disease.

Celgene intends to seek US approval for the psoriasis indication in the latter half of the year. European approval of psoriatic arthritis and psoriasis indications is expected to be sought in the second half of the year on a combined basis.

Celgene, a biopharmaceutical company, currently carries a Zacks Rank #2 (Buy). Other biopharma stocks, such as Athersys Inc. (ATHX - Snapshot Report), XOMA Corporation (XOMA - Snapshot Report) and Santarus, Inc. are comparatively well placed and carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
GENERAL FINA GFN 8.20 +5.67%
QIHOO 360 TE QIHU 91.57 +4.38%
VIPSHOP HOLD VIPS 140.01 +3.49%
INVESTMENT T ITG 19.16 +3.34%
VERTEX ENERG VTNR 7.38 +3.07%